ACIP Meeting: COVID-19 Vaccine Shared Decision-Making
- This text details concerns and debates raised during a September 19,2025 meeting of the Advisory Committee on Immunization Practices (ACIP) regarding COVID-19 mRNA vaccines.
- * Potential Long-Term Immune System Changes: Concerns were raised about possible lasting effects on the immune system.
- * DNA Contamination: While concerns were voiced, the WHO, FDA, and other regulatory agencies maintain that any residual DNA is minimal and poses no health risk.
Summary of Concerns Raised at the September 19,2025 ACIP Meeting Regarding COVID-19 Vaccines
This text details concerns and debates raised during a September 19,2025 meeting of the Advisory Committee on Immunization Practices (ACIP) regarding COVID-19 mRNA vaccines. Here’s a breakdown of the key points:
Key Concerns Expressed:
* Potential Long-Term Immune System Changes: Concerns were raised about possible lasting effects on the immune system.
* Biodistribution: Questions were asked about where vaccine components travel within the body beyond the injection site.
* frameshifting & DNA Contamination: Some members expressed worry about unintended genetic changes (frameshifting) and the presence of DNA contamination in the vaccines, with a potential link to cancer being suggested.
* Pharmacokinetics: Dr.Kirk Milhoan questioned the thoroughness of the pharmacological testing before vaccine release and why the vaccine wasn’t recalled given reports of contamination.
Debate & Counterarguments:
* DNA Contamination: While concerns were voiced, the WHO, FDA, and other regulatory agencies maintain that any residual DNA is minimal and poses no health risk.
* Correlates of protection: A significant debate occurred between Dr. Robert Malone and Dr. Cody Meissner regarding what immune responses reliably predict vaccine effectiveness.
* Malone: Argued that no established correlates of protection exist for COVID-19 vaccines.
* Meissner: cited research (from The New England Journal of Medicine) suggesting that levels of anti-spike IgG antibodies and neutralizing antibody titers do correlate with protection, at least in the short term.
Critically importent Note: The text highlights that studies cited in support of concerns frequently enough used small sample sizes and potentially selective reporting methods.